TELA
TELA Bio, Inc.NASDAQHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
5.16
P/S
0.35
EV/EBITDA
-1.03
DCF Value
$1.45
FCF Yield
-101.7%
Div Yield
0.0%
Margins & Returns
Gross Margin
67.7%
Operating Margin
-42.0%
Net Margin
-48.4%
ROE
-441.5%
ROA
-47.7%
ROIC
-53.2%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $20.9M | $-9.0M | $-0.17 |
| FY 2025 | $80.3M | $-38.8M | $-0.83 |
| Q3 2025 | $20.7M | $-8.6M | $-0.19 |
| Q2 2025 | $20.2M | $-9.9M | $-0.22 |
Analyst Ratings
View AllTrading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
0.99
TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. It provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. The company markets its products through a single direct sales force, principally in the United States. TELA Bio, Inc. was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.